Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2021-02-25 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于2020年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as an announcement regarding the 2020 annual performance quick report (业绩快报公告). It contains preliminary financial data for the year 2020, including revenue, profit, net income, and quarterly revenue comparisons. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the 2020 annual report. The document is relatively short (1999 characters) and serves as a summary or quick update rather than a full annual report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K). Instead, it is a brief earnings update or performance summary for the year. This fits the definition of an Earnings Release (ER), which is an initial announcement of periodical financial results with key highlights only. FY 2020
2021-02-25 Chinese
江苏浩欧博生物医药股份有限公司关于监事暨核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a company supervisor and core technical personnel. It details the individual's departure, the impact on the company, and the measures taken to address the vacancy. There is no financial data, no mention of financial results, no regulatory filings of financial nature, no voting results, no capital changes, and no legal proceedings. The content focuses on management changes, specifically the departure of a senior technical and supervisory person. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-02-25 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司募投项目金额调整的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Huatai United Securities regarding the adjustment of the amount of funds raised for investment projects by Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It references regulatory approvals, fundraising amounts, board and supervisory meetings approving the adjustments, and compliance with laws and regulations. The document is a formal verification or audit opinion related to the use and adjustment of raised funds, not a full annual or interim financial report. It does not contain comprehensive financial statements or detailed financial performance data. It is also not a simple announcement or a certification letter but a detailed verification opinion by the sponsor institution. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and verification opinions related to accounting and fundraising compliance. Q1 2021
2021-01-25 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于第二届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. regarding matters discussed at the company's second board of directors' sixth meeting. It references compliance with laws and regulations related to the use of raised funds and adjustments to investment project amounts. The content focuses on governance and regulatory compliance related to board decisions and fundraising use, rather than presenting financial statements or audit results. The document is not a full financial report, earnings release, or audit report, but rather a formal board/management related opinion on specific corporate governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to board opinions, not a report publication or regulatory filing. Confidence is high due to clear governance context and terminology.
2021-01-25 Chinese
江苏浩欧博生物医药股份有限公司关于公司募投项目金额调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the amount of funds raised for investment projects by Jiangsu Haobo Biomedical Co., Ltd. It details the original and adjusted amounts of funds raised, the approval by the board and supervisory committee, and opinions from independent directors and the sponsoring institution. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on changes to the capital raised and its allocation. This fits the category of a Capital/Financing Update (CAP), as it relates to fundraising and capital structure changes. The document length is 2404 characters, which is consistent with an announcement rather than a full report.
2021-01-25 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司以募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from the sponsor institution (华泰联合证券有限责任公司) regarding the use of raised funds by 江苏浩欧博生物医药股份有限公司 to replace self-raised funds previously invested in projects and issuance expenses. It references regulatory guidelines and includes detailed financial figures about the fundraising and fund replacement. The document is a formal verification or audit-related opinion rather than a full annual or interim report. It does not contain comprehensive financial statements or management discussion but focuses on compliance and verification of fund usage. This fits the category of an Audit Report / Information (AR), as it is a standalone audit/verification report related to fundraising and fund usage compliance, not a full annual report or earnings release. The document length is 3408 characters, which is consistent with a detailed audit opinion rather than a brief announcement or a full report. Q1 2021
2021-01-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.